semaglutide major side effects Ozempic: is a GLP-1 receptor agonist used for type 2 diabetes and cardiovascular risk reduction in selected patients, commonly causing nausea, vomiting, diarrhea, constipation, abdominal pain, reduced appetite, and weight loss Comparative safety and side effects

Results SLR The clinical SLR identified 42 unique RCTs for adults ( 18 years) with either obesity or overweight with at least one obesity-related complication which reported on the interventions of interest (tirzepatide, semaglutide and liraglutide)

Metabolic ratedetermined partly by age, muscle mass, and thyroid functioncreates variation in how quickly different people respond to the appetite-suppressing effects of semaglutide

At 3 years of follow-up, tirzepatide use led to a sustained mean loss of weight of 20% with less likelihood of deterioration to diabetes in persons with obesity and prediabetes when compared to placebo [137]

Levothyroxine dose and risk of atrial fibrillation: a nested case-control study